Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data.

Finn, RS; Raoul, J.L.; Manekas, Demetrios; Baudelet, Christine; Walters, Ian

doi:10.1200/jco.2010.28.15_suppl.4096

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients had a median OS of 10 months, with no treatment-related deaths [155]. Brivanib alaninate also showed activity as a second-line post-sorafenib systemic treatment in 41 patients with HCC [156]. The results in 101 HCC patients receiving brivanib alaninate show that disease control (CR plus PR plus SD) was achieved in 76/101 under modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria [157].…”

Section: Brivanib Alaninatementioning

confidence: 96%

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Sato¹,

Mori

2011

CMC

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide. Unresectable or metastatic HCC has a poor prognosis, and systemic cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. However, there has been increasing interest in developing novel molecularly targeted agents in HCC due to the accumulation of knowledge of cell signaling and molecular carcinogenesis. Furthermore, some of these agents have proven to be efficacious in other traditionally challenging carcinomas, such as renal cell carcinoma. Recently, a phase III, randomized, placebo-controlled trial demonstrated that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor and Ras kinase, improves overall survival (OS) in patients with advanced HCC. This seminal study described the first agent to improve OS in HCC and began a new era of molecule-targeted cancer therapies. Currently, many novel molecularly targeted agents are under evaluation in clinical trials. In this review, we comprehensively summarize the molecular pathogenesis, targets, and signal transduction pathways involved in HCC. We also detail the current status of molecularly targeted agents that are under clinical development in advanced HCC, including the mechanisms of action of these agents.

show abstract

Section: Brivanib Alaninatementioning

confidence: 96%

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Sato¹,

Mori

2011

CMC

View full text Add to dashboard Cite

show abstract

“…Finally, the relative value of mRECIST when compared with mWHO criteria has been evaluated by Finn et al at the ASCO 2010 annual meeting [58]. Using the data from a phase II trial with brivanib, a multikinase inhibitor, they found a relevant discrepancy in the responses between mWHO (5 of 101) and mRECIST (19 of 101) criteria.…”

Section: Criteria For the Assessment Of Radiological Responsementioning

confidence: 99%

Methodological assessment of HCC literature

Daniele

Costa²,

Lorusso

et al. 2013

Annals of Oncology

View full text Add to dashboard Cite

Despite the fact that the hepatocellular carcinoma (HCC) represents a major health problem, very few interventions are available for this disease, and only sorafenib is approved for the treatment of advanced disease. Of note, only very few interventions have been thoroughly evaluated over time for HCC patients compared with several hundreds in other, equally highly lethal, tumours. Additionally, clinical trials in HCC have often been questioned for poor design and methodological issues. As a consequence, a gap between what is measured in clinical trials and what clinicians have to face in daily practice often occurs. As a result of this scenario, even the most recent guidelines for treatment of HCC patients use low strength evidence to make recommendations. In this review, we will discuss some of the potential methodological issues hindering a rational development of new treatments for HCC patients.

show abstract

Targeted Agents and Systemic Therapy in Hepatocellular Carcinoma

Ang

O'Reilly

Abou‐Alfa

2012

Multidisciplinary Treatment of Hepatocellular Carcinoma

View full text Add to dashboard Cite

Cytotoxic chemotherapy, hormonal agents, and immunotherapy have been tested in hepatocellular cancer (HCC) with marginal efficacy to date. Recent insights into the molecular pathogenesis of HCC have identified several aberrant signaling pathways that have served as targets for novel therapeutic agents. These discoveries have been translated into the clinical realm with the use of the antiangiogenic and the Raf kinase inhibitor, sorafenib, and have revealed the potential of targeted agents to produce clinically meaningful survival benefits in patients with advanced HCC. Efforts continue in the quest to improve the outcome of HCC patients through the development and evaluation of other targeted agents, and to better understand the interactions between the underlying disease biology and response to therapy. Several pathways are now implicated in hepatocarcinogenesis and agents that target these pathways continue to be developed.

show abstract

Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data.

Cited by 4 publications

References 0 publications

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Methodological assessment of HCC literature

Targeted Agents and Systemic Therapy in Hepatocellular Carcinoma

Contact Info

Product

Resources

About